A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2018
At a glance
- Drugs VRC-CHKVLP059-00-VP (Primary)
- Indications Chikungunya virus infections
- Focus Pharmacodynamics
- Sponsors PaxVax
- 13 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 25 Apr 2018 According to PaxVax media release,company expects results in early 2019
- 25 Apr 2018 According to PaxVax media release,Status changed from not yet recruiting to recruiting.